195 related articles for article (PubMed ID: 15134193)
1. Safety and efficacy of a NRTI-sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1-infected children.
Fraaij PL; Neubert J; Bergshoeff AS; van Rossum AM; Hartwig NG; Schroten H; Korn K; Burger DM; de Groot R; Niehues T
Antivir Ther; 2004 Apr; 9(2):297-9. PubMed ID: 15134193
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of an anti-retroviral combination regimen including either efavirenz or lopinavir-ritonavir with a backbone of two nucleoside reverse transcriptase inhibitors.
Panagopoulos P; Tsiodras S; Antoniadou A; Katsarolis I; Papadopoulos A; Poulakou G; Giamarellou H
Clin Microbiol Infect; 2006 May; 12(5):486-9. PubMed ID: 16643529
[TBL] [Abstract][Full Text] [Related]
3. Class-sparing regimens for initial treatment of HIV-1 infection.
Riddler SA; Haubrich R; DiRienzo AG; Peeples L; Powderly WG; Klingman KL; Garren KW; George T; Rooney JF; Brizz B; Lalloo UG; Murphy RL; Swindells S; Havlir D; Mellors JW;
N Engl J Med; 2008 May; 358(20):2095-106. PubMed ID: 18480202
[TBL] [Abstract][Full Text] [Related]
4. Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison.
De Luca A; Cozzi-Lepri A; Antinori A; Zaccarelli M; Bongiovanni M; Di Giambenedetto S; Marconi P; Cicconi P; Resta F; Grisorio B; Ciardi M; Cauda R; Monforte Ad; ; ; ;
Antivir Ther; 2006; 11(5):609-18. PubMed ID: 16964829
[TBL] [Abstract][Full Text] [Related]
5. Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen.
Fischl MA; Collier AC; Mukherjee AL; Feinberg JE; Demeter LM; Tebas P; Giuliano M; Dehlinger M; Garren K; Brizz B; Bassett R
AIDS; 2007 Jan; 21(3):325-33. PubMed ID: 17255739
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-sparing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patients.
Allavena C; Ferré V; Brunet-François C; Delfraissy JF; Lafeuillade A; Valantin MA; Bentata M; Michelet C; Poizot-Martin I; Dailly E; Launay O; Raffi F;
J Acquir Immune Defic Syndr; 2005 Jul; 39(3):300-6. PubMed ID: 15980689
[TBL] [Abstract][Full Text] [Related]
7. Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009.
Boyd MA; Siangphoe U; Ruxrungtham K; Duncombe CJ; Stek M; Lange JM; Cooper DA; Phanuphak P
HIV Med; 2005 Nov; 6(6):410-20. PubMed ID: 16268823
[TBL] [Abstract][Full Text] [Related]
8. [Efavirenz--comprehensive status of studies].
MMW Fortschr Med; 2005 Apr; 147 Spec No 1():79-81. PubMed ID: 16385886
[No Abstract] [Full Text] [Related]
9. Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children.
Larrú B; Resino S; Bellón JM; de José MI; Fortuny C; Navarro ML; Gurbindo MD; Ramos JT; Soler Palacín P; Léon JA; Asensi M; Mellado MJ; Muñoz-Fernández MA
J Antimicrob Chemother; 2008 Jan; 61(1):183-90. PubMed ID: 18025025
[TBL] [Abstract][Full Text] [Related]
10. Safety and antiviral response at 12 months of lopinavir/ritonavir therapy in human immunodeficiency virus-1-infected children experienced with three classes of antiretrovirals.
Ramos JT; De José MI; Dueñas J; Fortuny C; González-Montero R; Mellado MJ; Mur A; Navarro M; Otero C; Pocheville I; Muñoz-Fernández MA; Cabrero E;
Pediatr Infect Dis J; 2005 Oct; 24(10):867-73. PubMed ID: 16220083
[TBL] [Abstract][Full Text] [Related]
11. First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohort.
Domingo P; Suárez-Lozano I; Torres F; Teira R; Lopez-Aldeguer J; Vidal F; Muñoz A; Viciana P; Lozano F; Vergara A; Roca B; García Alcalde ML; Cosín J; Terrón A; Galindo MJ; Geijo P; Ribera E; Gonzalez J; Sanchez T; Lacalle JR; Garrido M
J Antimicrob Chemother; 2008 Jun; 61(6):1348-58. PubMed ID: 18356150
[TBL] [Abstract][Full Text] [Related]
12. Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients.
Moltó J; Ruiz L; Valle M; Martinez-Picado J; Bonjoch A; Bravo I; Negredo E; Heilek-Sneider GM; Clotet B
Antivir Ther; 2006; 11(1):47-51. PubMed ID: 16518959
[TBL] [Abstract][Full Text] [Related]
13. Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial.
Hansen AB; Obel N; Nielsen H; Pedersen C; Gerstoft J
HIV Med; 2011 Mar; 12(3):157-65. PubMed ID: 20722752
[TBL] [Abstract][Full Text] [Related]
14. Switching to lopinavir/ritonavir with or without abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine.
Bernardino JI; Pulido F; Martinez E; Arrizabalaga J; Domingo P; Portilla J; Ocampo A; Muñoz J; Torres R; Arribas JR;
J Antimicrob Chemother; 2013 Jun; 68(6):1373-81. PubMed ID: 23386261
[TBL] [Abstract][Full Text] [Related]
15. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.
Rudin C; Burri M; Shen Y; Rode R; Nadal D; ;
Pediatr Infect Dis J; 2008 May; 27(5):431-7. PubMed ID: 18382386
[TBL] [Abstract][Full Text] [Related]
16. Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial.
Ghosn J; Flandre P; Cohen-Codar I; Girard PM; Chaix ML; Raffi F; Dellamonica P; Ngovan P; Norton M; Delfraissy JF;
HIV Med; 2010 Feb; 11(2):137-42. PubMed ID: 19682100
[TBL] [Abstract][Full Text] [Related]
17. First-line efavirenz versus lopinavir-ritonavir-based highly active antiretroviral therapy for naive patients.
Manfredi R; Calza L; Chiodo F
AIDS; 2004 Nov; 18(17):2331-3. PubMed ID: 15577549
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team.
Starr SE; Fletcher CV; Spector SA; Yong FH; Fenton T; Brundage RC; Manion D; Ruiz N; Gersten M; Becker M; McNamara J; Mofenson LM; Purdue L; Siminski S; Graham B; Kornhauser DM; Fiske W; Vincent C; Lischner HW; Dankner WM; Flynn PM
N Engl J Med; 1999 Dec; 341(25):1874-81. PubMed ID: 10601506
[TBL] [Abstract][Full Text] [Related]
19. Positive virological outcome after lopinavir/ritonavir salvage therapy in protease inhibitor-experienced HIV-1-infected children: a prospective cohort study.
Resino S; Bellón JM; Ramos JT; Gonzalez-Rivera M; de José MI; González MI; Gurbindo D; Mellado MJ; Cabrero E; Muñoz-Fernández MA
J Antimicrob Chemother; 2004 Nov; 54(5):921-31. PubMed ID: 15472006
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor.
Solas C; Poizot-Martin I; Drogoul MP; Ravaux I; Dhiver C; Lafeuillade A; Allegre T; Mokhtari M; Moreau J; Lepeu G; Petit N; Durand A; Lacarelle B
Br J Clin Pharmacol; 2004 Apr; 57(4):436-40. PubMed ID: 15025741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
